Full Press Release Details
Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of
quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch
second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's
and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability
to host conference call and webcast today, March 26, at 4:30 p.m. ET
B.C., Grapevine, TX, March 26, 2026. Alpha Cognition Inc. (ACOG: NASDAQ) ("Alpha Cognition", "ACI",
or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,
today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL - the first new oral
Alzheimer's treatment approved in more than 15 years. In the fourth quarter, we saw strong growth in demand, with December representing
our strongest month since launch. We're encouraged by the increasing rates of repeat ordering, indicating ZUNVEYL is moving beyond
initial trial and becoming increasingly integrated into routine management in long-term care," said Michael McFadden, Chief Executive
Officer of Alpha Cognition.
we also executed a second national PBM contract, bringing us to two of the four major PBMs relevant to long-term care. Combined with
the consistent clinical feedback we're hearing on ZUNVEYL's tolerability and behavioral profile, we believe we are well positioned
to continue driving adoption as payer pull-through improves in 2026. We enter the year well-capitalized and focused on expanding our
commercial footprint, deepening prescriber engagement, and advancing toward operational profitability in 2027."
Commercial Performance
and Upcoming Business, Clinical, and Operational Highlights
Year Fiscal 2025 Financial Results
Cognition will host a conference call and webcast today, March 26 at 4:30 p.m. Eastern Time. To access the live conference call by phone,
dial 877-407-9039 or 201-689-8470. The live audio webcast will be accessible at https://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0.
An archived version of the webcast will be available for replay on the Alpha Cognition Investor Relations page following the event.
Alpha Cognition Inc.
Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative
diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ("mTBI"), for which
there are currently no approved treatment options.
is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected
minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it
binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062
is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation
for Cognitive Impairment with mTBI.
further information:
Advisors, PJ Kelleher
is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL.
Serious skin reactions have occurred.
Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported
in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use
of this drug should not be resumed, and alternative therapy should be considered.
See Drug Interactions Section
Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading
to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors,
both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse
effects on cardiac conduction.
treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.
Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely
for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal
anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either
peptic ulcer disease or gastrointestinal bleeding.
has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with
Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may
cause bladder outflow obstruction.
Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may
also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures
while taking ZUNVEYL.
Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma
or obstructive pulmonary disease. Monitor for respiratory adverse reactions.
most common adverse reactions with galantamine tablets ( 5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications.
with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given
concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such
IN SPECIFIC POPULATIONS
Based on animal data may cause fetal harm.
Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage
adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.
Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore,
a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.
are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Please click here for Full Prescribing Information.
news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical
fact, any information contained in this news release may be a forward-looking statement that reflects the Company's current views
about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual
results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these
forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization
of ZUNVEYL, statement regarding the timing and potential outcomes of the Company's ongoing clinical and preclinical studies, statements
regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated
operations of the Company. In some cases, you can identify forward-looking statements by the words "may," "might,"
"will," "could," "would," "should," "expect," "intend," "plan,"
"objective," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue" and "ongoing,"
or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company
believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination
of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure
that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain
risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL,
risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk
related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related
to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our
ongoing clinical trials and other risks as described in the Company's filings with Canadian securities regulatory authorities and
available at www.sedar.com and the Company's filings with the United States Securities and Exchange Commission (the "SEC"),
including those risk factors under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K
filed with the SEC on March 31, 2025 and the Company's other filings with the SEC available at www.sec.gov. These forward-looking
statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking
statements for any reason, even if new information becomes available in the future, except as required by law.
regarding Key Performance Indicators
the company began commercial sales of ZUNVEYL in 2025, management has identified several key performance indicators that it utilizes
to assess the progress of commercialization and sale of ZUNVEYL and the success of its operations period over period. These key performance